Johannes Czernin
Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.
Nuclear medicine physician and editor-in-chief of the Journal of Nuclear Medicine. Co-led the UCLA/UCSF prospective PSMA PET trials behind FDA approval and the US 177Lu-PSMA-617 experience.
| Title | Journal | Year |
|---|---|---|
| Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial | JAMA Oncology | 2019 |
| Molecular imaging in the development of cancer therapeutics | Annual Review of Medicine | 2006 |
Pages like this
not linked directly; found by shared links- PersonJeremie Calais
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonThomas A. Hope
Shares PET (positron emission tomography), PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- ProductGallium-68 gozetotide (PSMA-11)
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, PSMA PET, Prostate cancer.
- PersonMichael J. Morris
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonShahneen Sandhu
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- TargetGRPR (gastrin-releasing peptide receptor)
Shares PET (positron emission tomography), Radioligand therapy (beta emitters), Prostate cancer.